Effective March 2, 2022, the GT Biopharma, Inc. (Registrant) appointed Michael Breen as the Registrant's Interim Chief Executive Officer with an increase in his annual base compensation to $515,000. Gregory Berk, M.D. ceased serving as the Registrant's Interim Chief Executive Officer, but will continue to serve as the Registrant's President of Research & Development and Chief Medical Officer, with a cost-of-living increase in his annual base compensation to $437,750.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.85 USD | -9.67% | -20.06% | -62.75% |
Jun. 07 | GT Biopharma, Inc. Announces CFO Changes | CI |
May. 21 | Top Midday Decliners | MT |
1st Jan change | Capi. | |
---|---|---|
-62.75% | 6.8M | |
+48.39% | 765B | |
-6.13% | 354B | |
+20.61% | 331B | |
+10.00% | 299B | |
+18.87% | 248B | |
-1.96% | 219B | |
+11.11% | 216B | |
+5.80% | 164B | |
-2.50% | 162B |
- Stock Market
- Equities
- GTBP Stock
- News GT Biopharma, Inc.
- GT Biopharma, Inc. Announces CEO Changes